← Back to context

Comment by cowsandmilk

19 days ago

GLP-1 drugs don’t require marketing. There are tons of people who have been prescribed them and aren’t being covered by insurance. Both Novo and Eli Lily are now selling them direct to consumers with prescriptions that don’t have insurance coverage.

The marketing isn't for the drugs.

They market the service that gives you the drugs with the smallest oversight possible. These services are becoming popular among people who shouldn't be taking GLP-1s (eating disorders, body dysmorphia, people who are too thin but want to lose more weight) because most of their providers are just trying to write prescriptions as fast as possible to collect their payments.

  • Also the elderly and poor who cannot afford the prescriptions.

    GLP-1 drugs range from $100-$200 a month from mail order compounding pharmacies, or $500 a month on "discount" plans from the drug makers.

    This change to FDA enforcement is going to prevent a lot of people from getting help.

    The positive impact of GLP-1 drugs is huge, but the price is out of reach for most people. The people who most benefit, elderly obese people at high risk of injury due to falls, who have a low quality of life from morbid obesity, are least able to afford access to the drugs.

    These compounding pharmacies were improving a lot of lives.

  • I'm obese. The drugs are approved. But without another condition they aren't covered by my HMO so I have to go outside.